Making CRISPR safer with new enzyme-based prediction tool
A new technique will help scientists choose the best available gene editing option for any given indication, making CRISPR technology safer, cheaper, and more effective. The tool is outlined in a September 7 article in Nature Biotechnology.  Discuss
Atara advances CAR-T technology with IND clearance
Atara Biotherapeutics said that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for ATA2271, a next-generation, autologous mesothelin-targeted chimeric antigen receptor T (CAR-T) cell therapy for patients with advanced mesothelioma.
Canbridge, UMass partner on gene therapies for neuromuscular diseases
Canbridge Pharmaceuticals has expanded its gene-therapy partnership with the University of Massachusetts (UMass) Medical School.
Customized gene therapies successfully target rare eye diseases
Can gene therapies prove effective for the treatment of rare genetic diseases? One company may have found a solution that incorporates a high degree of customization, manufacturing expertise, and years' worth of knowledge.  Discuss
New CRISPR-repressor system improves efficiency of gene therapies
Researchers have developed a CRISPR-based system that can simultaneously provide transcriptional control and gene editing on demand to improve the efficacy of gene therapies. The details were published in Nature Cell Biology on September 3.  Discuss
New gene therapy destroys latent oral herpes in mice
Researchers recently reported that they were able to eliminate latent herpes simplex virus 1 in mice using a new gene editing technique that targets the root cause of oral herpes. The findings were published on August 18 in Nature Communications.  Discuss
Kite submits BLA for CAR-T in non-Hodgkin lymphomas
Kite, a Gilead company, has submitted a supplemental biologics license application (sBLA) to the U.S. Food and Drug Administration for axicabtagene ciloleucel (Yescarta) for the treatment of relapsed or refractory follicular lymphoma or marginal zone lymphomas after two or more prior therapies.
Magenta to explore targeted gene editing to cure HIV
Clinical-stage biotechnology company Magenta Therapeutics has joined a broad-based research effort to explore gene- and cell-based approaches to cure HIV.
Gyros launches new product to support cell & gene therapy manufacturing
Gyros Protein Technologies introduced a new product for adeno-associated virus vector titer determination.
Unum Therapeutics transfers BOXR cell-based therapy to Sotio
Unum Therapeutics has sold its Bolt-on Chimeric Receptor (BOXR) cell-based therapy technology to immuno-oncology firm Sotio.
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter